It has been speculated by some industry watchers that the European Medicines Agency will grant approval for the first wave of biosimilars this year.
Finalisation of guidelines is expected within the next six months.
Amgen continues to be an H&K client in the US and Portugal. The agency won the European project account following an agency review last year (PRWeek, 5 August 2005).
Have you registered with us yet?
Register now to enjoy more articles and free email bulletinsRegister